These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 36368608)

  • 41. Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Carbamazepine.
    García MA; Cristofoletti R; Abrahamsson B; Groot DW; Parr A; Polli JE; Mehta M; Shah VP; Tomakazu T; Dressman JB; Langguth P
    J Pharm Sci; 2021 May; 110(5):1935-1947. PubMed ID: 33610571
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biowaiver: an alternative to in vivo pharmacokinetic bioequivalence studies.
    Mishra V; Gupta U; Jain NK
    Pharmazie; 2010 Mar; 65(3):155-61. PubMed ID: 20383933
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biowaiver monograph for immediate-release solid oral dosage forms: fluconazole.
    Charoo N; Cristofoletti R; Graham A; Lartey P; Abrahamsson B; Groot DW; Kopp S; Langguth P; Polli J; Shah VP; Dressman J
    J Pharm Sci; 2014 Dec; 103(12):3843-3858. PubMed ID: 25312492
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Theoretical Investigation of Dissolution Test Criteria for Waiver of Clinical Bioequivalence Study.
    Sugano K
    J Pharm Sci; 2016 Jun; 105(6):1947-1951. PubMed ID: 27238491
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Investigating the Discriminatory Power of BCS-Biowaiver in Vitro Methodology to Detect Bioavailability Differences between Immediate Release Products Containing a Class I Drug.
    Colón-Useche S; González-Álvarez I; Mangas-Sanjuan V; González-Álvarez M; Pastoriza P; Molina-Martínez I; Bermejo M; García-Arieta A
    Mol Pharm; 2015 Sep; 12(9):3167-74. PubMed ID: 26287948
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Cephalexin Monohydrate.
    Plöger GF; Quizon PM; Abrahamsson B; Cristofoletti R; Groot DW; Parr A; Langguth P; Polli JE; Shah VP; Tajiri T; Mehta MU; Dressman J
    J Pharm Sci; 2020 Jun; 109(6):1846-1862. PubMed ID: 32240696
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regulatory Perspectives on Strength-Dependent Dissolution Profiles and Biowaiver Approaches for Immediate Release (IR) Oral Tablets in New Drug Applications.
    Suarez-Sharp S; Delvadia PR; Dorantes A; Duan J; Externbrink A; Gao Z; Ghosh T; Miksinski SP; Seo P
    AAPS J; 2016 May; 18(3):578-88. PubMed ID: 26928450
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Physiologically Based Biopharmaceutics Model for Selumetinib Food Effect Investigation and Capsule Dissolution Safe Space - Part I: Adults.
    Pepin XJH; Hammarberg M; Mattinson A; Moir A
    Pharm Res; 2023 Feb; 40(2):387-403. PubMed ID: 36002614
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluating the bioequivalence of two pitavastatin calcium formulations based on IVIVC modeling and clinical study.
    Wang J; Chen J; Wang L; Yang D; Shao R; Lou H; Ruan Z; Jiang B
    Clin Transl Sci; 2023 Jan; 16(1):85-91. PubMed ID: 36178248
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Classification of torasemide based on the Biopharmaceutics Classification System and evaluation of the FDA biowaiver provision for generic products of CLASS I drugs.
    Khan MZ; Rausl D; Radosević S; Filić D; Danilovski A; Dumić M; Knezević Z
    J Pharm Pharmacol; 2006 Nov; 58(11):1475-82. PubMed ID: 17132210
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oral biopharmaceutics tools: recent progress from partnership through the Pharmaceutical Education and Research with Regulatory Links collaboration.
    O'Dwyer PJ; Box KJ; Dressman J; Griffin BT; Henze LJ; Litou C; Pentafragka C; Statelova M; Vertzoni M; Reppas C
    J Pharm Pharmacol; 2021 Mar; 73(4):437-446. PubMed ID: 33793836
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of the Biopharmaceutical Classification System in early drug development.
    Ku MS
    AAPS J; 2008; 10(1):208-12. PubMed ID: 18446521
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Screening of Bioequivalent Extended-Release Formulations for Metformin by Principal Component Analysis and Convolution-Based IVIVC Approach.
    Zhang Y; Liu H; Tang MJ; Ho NJ; Shek TL; Yang Z; Zuo Z
    AAPS J; 2021 Mar; 23(2):38. PubMed ID: 33665728
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro and In silico biopharmaceutic regulatory guidelines for generic bioequivalence for oral products: Comparison among various regulatory agencies.
    Kollipara S; Ahmed T; Bhattiprolu AK; Chachad S
    Biopharm Drug Dispos; 2021 Jul; 42(7):297-318. PubMed ID: 34019712
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen.
    Loisios-Konstantinidis I; Cristofoletti R; Fotaki N; Turner DB; Dressman J
    Eur J Pharm Sci; 2020 Feb; 143():105170. PubMed ID: 31783158
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Mechanistic Physiologically-Based Biopharmaceutics Modeling (PBBM) Approach to Assess the In Vivo Performance of an Orally Administered Drug Product: From IVIVC to IVIVP.
    Bermejo M; Hens B; Dickens J; Mudie D; Paixão P; Tsume Y; Shedden K; Amidon GL
    Pharmaceutics; 2020 Jan; 12(1):. PubMed ID: 31963448
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of a Novel Gastric Process Simulation Model: The Successful Assessment of Bioequivalence and Bioinequivalence of a Biopharmaceutics Classification System Class II Weak Acid Drug.
    Zenda N; Tagami T; Ozeki T
    Biol Pharm Bull; 2022; 45(3):364-373. PubMed ID: 35228402
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Support Waivers of
    Loisios-Konstantinidis I; Dressman J
    Mol Pharm; 2021 Jan; 18(1):1-17. PubMed ID: 33320002
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements.
    Davit BM; Kanfer I; Tsang YC; Cardot JM
    AAPS J; 2016 May; 18(3):612-8. PubMed ID: 26943914
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk assessment for extending the Biopharmaceutics Classification System-based biowaiver of immediate release dosage forms of fluconazole in adults to the paediatric population.
    Charoo NA; Cristofoletti R; Dressman JB
    J Pharm Pharmacol; 2015 Aug; 67(8):1156-69. PubMed ID: 25828546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.